Compare BTDR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | ADPT |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | Singapore | United States |
| Employees | N/A | 624 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 2021 | 2019 |
| Metric | BTDR | ADPT |
|---|---|---|
| Price | $17.71 | $17.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $22.70 | $17.78 |
| AVG Volume (30 Days) | ★ 11.5M | 2.0M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $72.51 | $3.98 |
| Revenue Next Year | $40.84 | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $7.04 | $9.96 |
| 52 Week High | $27.80 | $20.76 |
| Indicator | BTDR | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 61.51 |
| Support Level | $10.83 | $14.87 |
| Resistance Level | $18.84 | $17.72 |
| Average True Range (ATR) | 1.81 | 1.22 |
| MACD | -0.19 | 0.30 |
| Stochastic Oscillator | 50.62 | 66.16 |
Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.